1. Show article details.

    Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

    GlobeNewswire – 4:30 PM ET 05/26/2022

    Repligen Corporation (RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov has been directly involved in the development and commercialization of multiple biotherapeutic modalities, including monoclonal antibodies, blood factors, gene therapy vectors and exosomes.

  2. Show article details.

    Repligen Corporation to Present at Upcoming Investor Conferences

    GlobeNewswire – 7:30 AM ET 05/25/2022

    Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at three upcoming investor conferences.

  3. Show article details.

    Repligen's Return On Capital Employed Insights

    Benzinga – 9:52 AM ET 05/02/2022

    According to Benzinga Pro, during Q1, Repligen earned $46.96 million, a 61.33% increase from the preceding quarter. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

  4. Show article details.

    10 Biggest Price Target Changes For Thursday

    Benzinga – 7:35 AM ET 04/28/2022

    Check out this: Adobe And 3 Other Stocks Insiders Are Selling Don't forget to check out our premarket coverage here .

  5. Show article details.

    62 Biggest Movers From Yesterday

    Benzinga – 4:17 AM ET 04/28/2022

    62 Biggest Movers From Yesterday

  6. Show article details.

    38 Stocks Moving In Wednesday's Mid-Day Session

    Benzinga – 12:09 PM ET 04/27/2022

     Gainers Vivakor, Inc. gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of up to $250 million.  Losers Molecular Partners AG shares dipped 37.6% to $8.60. The company's collaborating partner Amgen for MP0310 will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review.  

  7. Show article details.

    Mid-Morning Market Update: Markets Open Higher; Dow Gains 300 Points

    Benzinga – 10:03 AM ET 04/27/2022

    U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.91% to 33,543.56 while the NASDAQ rose 1.55% to 12,683.73. The S&P also rose, gaining, 1.19% to 4,224.93.

  8. Show article details.

    The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

    Benzinga – 8:45 AM ET 04/27/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. Pfizer Inc  and BioNTech SE  have submitted an FDA Emergency Use Authorization application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age.

  9. Show article details.

    Recap: Repligen Q1 Earnings

    Benzinga – 7:51 AM ET 04/27/2022

      Repligen reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Repligen beat estimated earnings by 27.78%, reporting an EPS of $0.92 versus an estimate of $0.72. Revenue was up $63.56 million from the same period last year.

  10. Show article details.

    BRIEF-Repligen Reports First Quarter 2022 Financial Results

    Reuters – 7:35 AM ET 04/27/2022

    Repligen Corp (RGEN): * REPLIGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL GUIDANCE. * Q1 GAAP EARNINGS PER SHARE $0.81. * Q1 REVENUE ROSE 45 PERCENT TO $206.4 MILLION. * QTRLY ADJUSTED FULLY DILUTED EPS INCREASED TO $0.92. * TOTAL REVENUE IS EXPECTED TO BE IN RANGE OF $770-$800 MILLION FOR FY 2022.

  11. Show article details.

    Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

    GlobeNewswire – 7:30 AM ET 04/27/2022

    —Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue WALTHAM, Mass., April 27, 2022 -- Repligen Corporation (RGEN), a life sciences company focused on...

  12. Show article details.

    Earnings Scheduled For April 27, 2022

    Benzinga – 5:04 AM ET 04/27/2022

      ** Deutsche Bank is projected to report earnings for its first quarter. ** Oshkosh is estimated to report quarterly earnings at $0.16 per share on revenue of $1.88 billion. ** Solid Biosciences is projected to report quarterly loss at $0.18 per share on revenue of $2.68 million. ** LG Display Co is likely to report quarterly earnings at $0.02 per share on revenue of $5.58 billion.

  13. Show article details.

    Stocks That Hit 52-Week Lows On Tuesday

    Benzinga – 1:44 PM ET 04/26/2022

      During Tuesday, 581 stocks hit new 52-week lows. Meta Platforms was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was AnPac Bio-Medical Science. During Tuesday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  14. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 12:01 PM ET 04/25/2022

      On Monday, 721 companies achieved new lows for the year. During Monday, the following stocks set new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  15. Show article details.

    Stocks That Hit 52-Week Lows On Friday

    Benzinga – 12:26 PM ET 04/22/2022

      On Friday, 431 companies hit new 52-week lows. Here are all the stocks that set new 52-week lows on Friday: Be sure to stay with Benzinga for further updates and market-moving news.

  16. Show article details.

    Repligen Earnings Conference Call Is Coming Up, Here's What You Need To Know

    Benzinga – 5:19 PM ET 04/20/2022

    Repligen will host a conference call at 08:30 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. Follow this link to access the live webcast. To listen to the call, dial 274-3999 or 317-5607. Earnings conference calls allow companies to talk about their recent earnings reports publicly, so that anyone who is interested can get more information on what happened and why it happened.

  17. Show article details.

    Stocks That Hit 52-Week Lows On Tuesday

    Benzinga – 11:38 AM ET 04/19/2022

      On Tuesday, 242 companies hit new 52-week lows. The stocks that set new 52-week lows on Tuesday: Be sure to stay with Benzinga for further updates and market-moving news.

  18. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 11:40 AM ET 04/18/2022

      On Monday, 466 companies hit new 52-week lows. Stocks that set new 52-week lows on Monday are as follows:   Be sure to monitor Benzinga for the news traders need!

  19. Show article details.

    Repligen to Report First Quarter 2022 Financial Results

    GlobeNewswire – 7:30 AM ET 04/13/2022

    Repligen Corporation (RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27, 2022. The conference call will be accessible by dialing toll-free 274-3999 for domestic callers and 317-5607 for international callers.

  20. Show article details.

    Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum

    GlobeNewswire – 7:30 AM ET 03/18/2022

    Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 22-23, 2022.

Page:

Today's and Upcoming Events

  • Jul
    25

    RGEN to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Apr
    27

    RGEN announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.